Physician profile
Syed K Raza
NPI 1457542805
$843.04
in general payments reported to CMS, 2019-2025
14 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Geriatric Psychiatry provider received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.87 · 2022: $147 · 2023: $215 · 2024: $180 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $658.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $294.00 | 2022-2025 | Cobenfy, Camzyos |
| Otsuka America Pharmaceutical, INC. | $120.28 | 2023-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $87.82 | 2023-2024 | Spravato |
| Supernus Pharmaceuticals, INC. | $68.13 | 2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $51.88 | 2024-2025 | Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $37.87 | 2019 | |
| Alkermes, INC. | $34.24 | 2023 | Aristada, Lybalvi, Vivitrol |
| Corium, LLC | $33.38 | 2023-2024 | Azstarys |
| Tempus Ai, INC | $27.63 | 2024 | |
| Avanir Pharmaceuticals, INC. | $22.16 | 2022 | |
| Lundbeck LLC | $17.00 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $16.36 | 2023 | Auvelity |
| Neurocrine Biosciences, INC. | $16.30 | 2025 | |
| Abbvie INC. | $15.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.